tbuckley/cabot-search huggingface dataset:
AB0725 Using a reduced joint count in measuring disease activity in psoriatic arthritis, is it legit?
Authors: M Vis, K Wervers, I Tchetverikov, A Gerards, M Kok, C Appels, L-A Korswagen, M Hazes, J Veris, H van Groenendaal, J Luime
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> In Psoriatic arthritis (PsA) the pattern of joint involvement seems to be more heterogenic than Rheumatoid Arthritis (RA). Therefor the 66/68 joint count is frequently used in PsA scores. In this study we would like to investigate whether using less extensive joint counts influences PsA disease activity measures <h3>Objectives</h3> To evaluate the effect of using a 28, 44 or 66/68 joint count on Minimal Disease Activity (MDA). <h3>Methods</h3> Newly diagnosed PsA patients were included in the Dutch Early south-west Psoriatic Arthritis Registry (DEPAR) study between August 2013 and January 2017. Joint scores at baseline and 6 months were calculated using a 28, 44 and 66/68 joint count. Consecutively MDA was calculated using each of these joint counts. MDA is defined as minimal disease activity in 5 out of 7 domains (swollen joints, tender joints, PASI, patient vas pain, patient vas global, HAQ, enthesitis) <h3>Results</h3> In total, 413 patients were included into the study, of which 320 had reached 6 months follow-up at the time of this abstract. Half of the patients were male (49%), and mean age was 50 years (SD 13.8). The percentage of patients with at least one involved joint (swollen or tender) at baseline decreased from 91% using the 66/68 score to 88% with 44 joints and then to 80% with a 28 joint count (Table 1). At 6 month these scores were 66% 63% and finally 56% respectively for the 66/68, 44 and 28 joint count. After 6 months, 96 patients (30%) had achieved MDA using the original 66/68 joint count. Using a 28 joint count, 10 more patients (10% of the MDA population) were classified as having achieved MDA. <h3>Conclusions</h3> Using reduced joint count joints in PsA misclassifies around 10% of patients as having no joint involvement. It also misclassifies about 10% of the MDA population of having achieved MDA while they have not. Full 66/68 joint counts remain recommended for measuring disease activity in PsA. <h3>Disclosure of Interest</h3> None declared
AB0949 The annual cost of patients with juvenile idiopathic arthritis
Authors: B Serpen, O Altug-Gucenmez, C Acari, MK Sozmen, B Makay, SE Unsal
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The management of juvenile idiopathic arthritis (JIA) includes various methods including such as medication, hospitalization, rehabilitation. <h3>Objectives</h3> To determine how much juvenile idiopathic arthritis cost; the components of this cost; how new treatments, i.e. biologics, improve the disease course and hospital expenditures. <h3>Methods</h3> This study was conducted in Dokuz Eylul University, Pediatric Rheumatology Unit between March 2015-March 2016. One-hundred six JIA patients who had a follow-up period of at least 1 year according to International Edmonton 2001 criteria were included. This retrospective cost study evaluated the data of these patients and calculated the direct cost for the follow-up period. Clinical data was collected from patient files that were in department9s archive and cost data was gathered from Probel Hospital Information Management system. Patient data form covering sociodemographic and clinical information, patient drug form and annual medical cost form was filled out for each patient. <h3>Results</h3> 58.5% (n=62) of patients was female and 41.5% (n=44) was male. The mean age was 12.0±4.3 years. 34.0% (n=36) of patients was oligoarticular type, 28.3% (n=30) was poliarticular type, 22.6% (n=24) was enthesitis related arthritis (ERA), 8,5% (n=9) was psoriatic type and 6.6% (n=7) was systemic type. The cost of medication counted for 88.3% (453244.94 TL) of total direct annual cost. Total direct medical cost was highest for ERA (n=7742.55±9891 TL). While the annual cost was calculated as 10451 TL per person for biologic using patients, for the patients using non-biologic treatments it was determined as 1472 TL per person. 1 TL=0.32 € 1 TL =0.35 $ <h3>Conclusions</h3> Medication is responsible for most of the total direct medical cost in patients with JIA. Our results showed concordance with previous studies on the subject. This situation could be attributed to biologic agents that are being used in treatment in recent years. More prospective studies on the effectiveness of cost of treatment, with greater amount of patient and more homogenous subgroups are needed. <h3>Disclosure of Interest</h3> None declared
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
Authors: M.R. Jones, H. Lim, Y. Shen, E. Pleasance, C. Ch'ng, C. Reisle, S. Leelakumari, C. Zhao, S. Yip, J. Ho, E. Zhong, T. Ng, D. Ionescu, D.F. Schaeffer, A.J. Mungall, K.L. Mungall, Y. Zhao, R.A. Moore, Y. Ma, S. Chia, C. Ho, D.J. Renouf, K. Gelmon, S.J.M. Jones, M.A. Marra, J. Laskin
Journal: Annals of Oncology (2017)
AB0032 Upregulation of CD64 expression on monocytes in patients with active adult-onset still's disease: a possible biomarker for assessing disease activity
Authors: E Oguro, T Shimizu, A Kikuchi-Taura, S Tsuji, Y Okita, M Shigesaka, H Matsuoka, T Nii, S Teshigawara, E Kudo-Tanaka, Y Harada, M Matsushita, S Ohshima, Y Saeki
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Adult-onset Still9s disease (AOSD) is a systemic inflammatory disease of unknown etiology. Overproduction of multiple inflammatory cytokines and subsequent hyperactivation of monocytes/macrophages are prominent characteristics of AOSD. However, there are no convenient and precise methods for evaluating monocyte/macrophage activation in AOSD. We previously reported that monocyte CD64 (mCD64) expression could be quantitatively measured by flow cytometry and its expression was tightly correlated with the activity of systemic lupus erythematosus. <h3>Objectives</h3> We examined the association between mCD64 expression and AOSD disease activity. <h3>Methods</h3> This was a prospective, single-center, observational study conducted between January 2013 and December 2016. Eleven active AOSD patients who fulfilled the Yamaguchi9s criteria for AOSD and had the modified Pouchot score of ≥2 were enrolled. The mCD64 expression levels were quantitatively measured by flow cytometry and individually assessed both before (Pouchot score ≥2) and after treatment (score 0). Other disease-related laboratory data, such as C-reactive protein, ferritin, and white blood cell count, were simultaneously measured. As a control, 16 active systemic lupus erythematosus (SLE) patients (SLE disease activity index ≥6), 22 active rheumatoid arthritis (RA) patients (disease activity score with 28-joint counts &gt;3.2), and 20 healthy controls (HC) (female, 55%; mean age, 38.7±9.1 years) were enrolled. Statistical analysis was performed by the Mann-Whitney and Wilcoxon-paired tests. <h3>Results</h3> The median mCD64 expression levels were 73,339 [interquartile range (IQR), 45,861–88,181] and 16,443 (IQR, 45,891–88,181) molecules/cell before and after treatment, respectively. Thus, mCD64 expression levels were significantly decreased during the inactive phase compared with those in the active phase in AOSD (p=0.0001). The mCD64 expression levels were significantly higher in patients with active AOSD than in those with active SLE [34,648 (IQR, 44,204–24,657) molecules/cell, p=0.001], active RA [25,167 (IQR, 35,778–22,301) molecules/cell, p&lt;0.0001], and in HC [14,174 (IQR, 13,413–17,774) molecules/cell, p&lt;0.0001]. <h3>Conclusions</h3> These results suggest that mCD64 expression levels are highly upregulated in AOSD and tightly correlated with disease activity. The mCD64 expression level may be a useful biomarker for assessing the disease activity of AOSD. <h3>References</h3> Rau M, et al. J Rheumatol. 2010 Nov;37(11):2369–76. Kikuchi-Taura A, et al. Lupus. 2015 Sep;24(10):1076–80. Pouchot J, et al. Medicine. 1991;70:118–36. <h3>Disclosure of Interest</h3> None declared
AB0849 Association between periodontitis and osteoporosis
Authors: M Brahem, M Jguirim, M Khemis, E Chebil, D Chaabouni, M Younes, T Ben Alaya, M Ben Khelifa, I Bejia, M Touzi, S Zrour, N Bergaoui
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Both periodontitis and osteoporosis have similar sign of bone resorption in nature and have multifactorial etiologic factors, although the mediator factors or mechanism may be different. How to prevent and treat these two bone-loss diseases is always an important issue in public health. However, the relationship of them is still uncertain. <h3>Objectives</h3> The aim of our study is to evaluate the relationship between periodentitis and osteoporosis. <h3>Methods</h3> Tunisian women aged from 30 to 60 years, who consulted the Rheumatology department of Fattouma Bourguiba university hospital between Febrary to December 2017. The measure the bone mineral density (BMD) using the dual-energy X-ray absorptiometry (DEXA), were recruited to participate in this case-control study. Among the 60 women selected, 30 were diagnosed with osteoporosis or osteopenia (T-score&lt; -1; cases) and 30 with normal T-score (T-score&gt; -1; controls). The oral examination was done by a dentist in the stomatology department in the same hospital. <h3>Results</h3> The mean age of patients with osteoporosis/osteopenia was 58.61±8.11 [51–81 and 56.07±9.72 [40–76] in the control group.the mean bone miniral density (BMD)in vertebral site was 0.856±0.090g/cm<sup>2</sup> and 1.216±0.185g/cm<sup>2</sup> in control group. In femoral site, it was 0.877±0.221g/cm<sup>2</sup> and 1.061±0.142g/cm<sup>2</sup> respectively. The mean T-score in vertebral site was -2.387±0.814 DS in osteoporosis/ osteopenia group and 0.643±1.587 DS in control group. In femoral site, it was -1.577±0.970 DS and 0.213±1.162 respectively.The oral examination showed an excessive tooth mobility in 60% and 36.7% of controls without a significant difference, a gingival recession in 50% and 30% of controls, the presence of periodontal pockets in 23.3% and 16.7% of controls without a significant difference, a plaque index ≥2 in 53,3% of osteoporosis/osteopenia patients and 63,3% of controls and a non rectilinear trajectory of mouth opening in 13,3% and 3,3% of controls. <h3>Conclusions</h3> Our study showed that patients with osteoporosis or osteopenia have a poor oral hygiene, but without significant difference with control group.However, patients who were diagnosed as osteoporosis must pay more attention to their periodontal health. Good oral hygiene maintenance might be a crucial factor for preventing the deterioration of osteoporosis progressing. <h3>References</h3> Yi-Fang Huang et al, The Impact of Oral Hygiene Maintenance on the Association Between Periodontitis and Osteoporosis; Medicine; Volume 95, Number 6, February 2016. Reddy MS. Osteoporosis and periodontitis: discussion, conclusions, and recommendations. Ann Periodontol. 2001;6:214–217. <h3>Disclosure of Interest</h3> None declared
ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Authors: Jeffrey R. Infante, Christoph M Ahlers, F. Stephen Hodi, Sophie Postel-Vinay, Jan H. M. Schellens, John Heymach, Karen A. Autio, Mary S. Barnette, Herbert Struemper, Maura Watmuff, Elaine Marie Paul, David Ross Kaufman, Jeffrey S. Weber, Axel Hoos
Journal: Journal of Clinical Oncology (2016)

TPS3107 Background: OX40 (CD134) is a potent costimulatory tumor necrosis factor receptor expressed on activated CD4+ and CD8+ T cells. OX40 agonism promotes T-cell division and survival, resulting in stimulation of both immune effector and memory functions, while also blocking the suppressive function of regulatory T cells. This holds potential to overcome immune resistance and enhance immune mediated anti-tumor activity with OX40 agonism, particularly in combination with checkpoint inhibition. GSK3174998 is a humanized IgG1 anti-OX40 agonistic monoclonal antibody identified through collaboration with MD Anderson Cancer Center and is currently in phase I development. Methods: This is an open-label, non-randomized, multicenter study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced or recurrent solid tumors: non-small cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, melanoma, bladder, soft tissue sarcoma, triple-negative breast cancer, and colorectal carcinoma displaying microsatellite instability. The study will be conducted in 2 parts in approximately 180 pts. Primary objectives are to determine safety, tolerability, and maximum tolerated or administered dose of GSK3174998 as a single agent (Part 1) and when administered in combination with 200 mg pembrolizumab (Part 2). Secondary objectives include evaluation of antitumor activity, response rate and duration, progression-free survival, and overall survival, pharmacokinetics, pharmacodynamic activity in the blood and tumor microenvironment, and immunogenicity. Adverse events will be monitored using NCI CTCAE v. 4.0. Radiographic imaging will be obtained every 12 weeks to assess clinical response defined by immune-related RECIST. Tumor biopsies and blood samples will be collected before and during treatment to allow investigation of candidate biomarkers which may predict clinical response. As of Feb 1, 2016, Cohorts 1 and 2 have completed without DLT and enrollment to Cohort 3 is ongoing. Clinical trial information: NCT02528357.
Left Main Revascularization in 2017
Authors: Ajay J. Kirtane, Robert O. Bonow
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Annals Story Slam - Karl's Story
Authors: Natalie Wong
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 September 2017Annals Story Slam - Karl's StoryFREENatalie Wong, MDNatalie Wong, MDFrom University of Toronto, Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0056 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Karl's Story "Karl's Story," by Dr. Natalie Wong (Duration 06:50)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Toronto, Toronto, Ontario, Canada.Current Author Address: Natalie Wong, MD, University of Toronto, Toronto, Ontario, Canada; e-mail, [email protected]ca. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: SS1 ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
THU0616 Patients' perception on disease progression and adherence to biologic therapy
Authors: E Cefai, D Balzan, C Mercieca, AA Borg
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Adherence to medication depends on several factors such as medication beliefs, psychosocial factors, illness beliefs and concerns. The consequences of non-adherence are not insignificant, both from the clinical and health economic aspects. <h3>Objectives</h3> To assess medication adherence of patients taking biologics who are in remission or who have low disease activity and patients9 perception of disease progression. <h3>Methods</h3> Forty-four consecutive patients attending a dedicated biologic clinic and treated with TNF inhibitors were interviewed following their visit. Patients were asked about adherence to treatment, adverse effects, concerns about biologics and their perception of disease progression. Demographic and disease activity data were recorded. <h3>Results</h3> Forty-four patients (23 females, 21 males) participated in the survey (21 suffered from rheumatoid arthritis, 17 from ankylosing spondylitis and 6 from psoriatic arthritis). The mean age was 55.1 (SD 12.62) years. The mean DAS28 was 2.26 (SD 1.03) and the mean BASDAI was 4.21 (SD 2.1). Minimal or no pain was reported by 75%, mild or no fatigue by 78% and 77% had no restriction of activities of daily living. Medication adherence was reported as high by 68% and moderate by 32%. There were no patients who had a low level of adherence. 5% of patients admitted to be unaware of the need to omit their biologic when ill and 40% when requiring surgery. One out of 4 patients reported to have experienced adverse events, most commonly infections. 19% claimed to be moderately or very concerned about the adverse effects. On further questioning about the severity of potential adverse effects, 45% were unsure as to what the severity might be. When asked about duration of therapy, 29% replied more than 10 years; whilst 71% were unsure on when, if ever, the biologic is going to be stopped. Patients were also asked whether they believed that the biologic had successfully stopped further joint damage and 68% replied yes, 9% replied no, whilst 23% were unsure. Of those who replied yes, this perception was based on the absence or reduction of symptoms. <h3>Conclusions</h3> In this cohort of patients with low disease activity or remission, a third of patients still reported sub-optimal adherence to TNF inhibitor use. The benefits of adherence to biologic therapies need to be reinforced at every visit and factors leading to non-adherence addressed. Adverse effects remain a major concern that needs to be addressed, even in patients who have been on biologics for many years and have sustained remission or low disease activity. A quarter of patients were unsure whether biologics have stopped joint damage. Patients9 perception of joint damage progression needs to be explored to find ways of making it more understandable to patients. <h3>Disclosure of Interest</h3> None declared
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Authors: Christopher D. Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G. M. Roemer, Edward C. Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J. Freeman, Donna Neuberg, F. Stephen Hodi, Xiaole Shirley Liu, Margaret A. Shipp, Scott J. Rodig
Journal: Blood (2017)
FRI0544 Clinical and demographic profile of patients consulting for fragility fractures in a hospital in colombia during the years 2014-2016: image of the colombian health system
Authors: DG Fernández-Άvila, DN Rincόn-Riaño, D Pinzόn, JM Gutiérrez
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoporosis represents a major public health problem due to the seriousness of a patient9s main complication: fracture. The lack of the Colombian health system for a structured public policy aiming diagnosis and early intervention generates a high volume of patients having fragility fractures. <h3>Objectives</h3> To describe the clinical and demographic characteristics of patients with fragility fractures seen in our hospital. To describe the risk factors for fragility fractures. To inquire about the patient9s knowledge about osteoporosis. To follow each case establishing whether after presenting the complication (fracture), the patient would receive an ambulatory treatment covered by the health insurance. <h3>Methods</h3> Cross-sectional descriptive study <h3>Results</h3> 111 patients mean age of 74.4 years (± 11.3 years), 84 (75.6%) were women. All consulted for osteoporotic fracture. The most frequent type of fracture was hip (51.4%), followed by vertebra (23.4%), wrist (22.5%) and humerus (4.5%). 87.4% (n=97) had no personal history of fracture and only 1% had a history of frailty fracture in a first-degree relative. Risk factors: 7.2% (n=8) used glucocorticoids, 3.6% (n=4) antiepileptics and 3.6% (n=4) warfarin. 21.6% (n=24) were smokers. 77.5% (n=86) had never previously undergone a densitometry despite the fact that, because of their age, they had indicated that this study had previously been performed. Knowledge of osteoporosis by patients: 49.5% (n=55) did not know that osteoporosis was present, 58.6% (n=65) did not know that fracture was the main complication of this disease and 62.2% =69) does not relate to fractures with osteoporosis. All patients were educated and sensitized about osteoporosis and the importance of diagnosis and treatment and they were given an order to perform densitometry at discharge, despite the above 24.3% (n=27) densitometry was performed in the next year of the fracture. As for treatment, 33.3% (n=37) received calcium plus vitamin D. Only 9.9% (n=11) received treatment for osteoporosis (7 patients with bisphosphonate and 4 with denosumab), none received teriparatide osteoformer therapy. <h3>Conclusions</h3> The present study demonstrates the lack of understanding by the Colombian patients about osteoporosis. Despite of clear indications described international guidelines, we have found a the lack of densitometry measurements on our follow up patients. More serious, only 10% of the patients received treatment for osteoporosis and none of them used a osteoformer therapy. This proves the suboptimal follow-up made by the health insurance companies of our country. Urgent educational and public health policies are needed. <h3>Disclosure of Interest</h3> None declared
慢性in vivo研究における神経微小電極からのデキサメタゾンの能動的に制御された放出【Powered by NICT】
Authors: C Boehler, C Kleber, N Martini, Y Xie, I Dryg, T Stieglitz, U G Hofmann, M Asplund
Journal: Biomaterials (2017)